Certara and The University of Manchester co-host inaugural model-based personalized drug dosing in healthcare conference

Clinical healthcare researchers, academic, and industry experts from eight countries collaborate to advance the goal of identifying the right drug dose for each patient.

“Through its modeling and simulation work, Certara has been working toward the goal of precision dosing — providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient,” said Certara CEO Edmundo Muniz. “Through this Summit and the 15 examples which were presented that showcased the successful use of modeling and simulation in the hospital research environment, we are confident that precision dosing in healthcare will become mainstream shortly.”

Professor Kay Marshall, head of the Manchester Pharmacy School and a speaker at the conference, said: “Everyone is different and this means that they react to drugs in different ways. The emerging precision dosing field harnesses the explosion of genomic data and various markers of bodily functions using mathematical modeling to ensure that individuals get the best possible treatment.”

Speakers from eight countries, representing research institutions, academia, pharmaceutical companies, former regulators, and legal authorities spoke at the Summit. Sessions were organized around special populations representing the most fragile and complex population cohorts, including oncology, HIV, pediatric, obese, renally-impaired, cell transplant, and adolescent psychiatric patients and pregnant women. In addition to demonstrating how modeling and simulation facilitated individualized dosing, the conference focused on linking personalized dosing and its impact on public health.

Certara Chief Scientific Officer Amin Rostami, who also serves as the chair of systems pharmacology at The University of Manchester, said: “We now understand more fully the sources of variability, the individual characteristics of each patient, which can drive dosing decisions. The successful case studies shared at this Summit demonstrate that we are now ready to take the next step toward individualized dosing in everyday health care.”